Influenza is a disease known to continue to afflict a large number f people and cause many deaths throughout the world. Influenza A and B are the two types of influenza that cause epidemic human disease. The influenza illness is characterized by the abrupt onset of fever, myalgia, headache, and sore throat. Amantadine and rimantadine have been used to treatment and prophylaxis of influenza, but these agents can only reduce symptomatic illness due to influenza A virus and are ineffective against influenza B virus. Inhibitors of influenza neuraminidase constitute a new class of anti-influenza agents that reduce replication of influenza A and influenza B. Vaccination against influenza virus is the primary strategy to reduce the morbidity and mortality associated with influenza.
Amantadine ; Fever ; Headache ; Humans ; Influenza A virus ; Influenza B virus ; Influenza, Human* ; Mortality ; Myalgia ; Neuraminidase ; Orthomyxoviridae ; Pharyngitis ; Rimantadine ; Vaccination

No abstract available.
Adult* ; Humans ; Urinary Tract Infections* ; Urinary Tract*

No abstract available.
Humans ; Liver Diseases* ; Liver*

No abstract available.
Humans ; Liver Diseases* ; Liver*

Treatment of peptic ulceration by suppression of gastric aeid, secretion with the histamine H,-receptor antagonist, cimetidine is now well established. Prior to the availability of ranitidine, cimetidine was the only histamine H2-receptor antagonist available for treatment of duodenal and gastric ulceration. The aim of this study was to compare the efficacy of ranitidine and cimetidine in accelerating the healing of duodenal ulcer. The therapeutic trials comparing ranitidine with cimetidine in a total of 44. out-patients with endoscopically diagnosed duodenal ulcer ivere entered into the study. 28 patients were treated with ranitidine 150mg twiee daily, and 16 patients with cimetidine 200 mg 4 times daily for 4 weeks. Overall endoscopic healing rates were 75%, on ranitidine and 64.3% on cimetidine, and so ranitidine appears to be slightly more effective than cimetidine although too small numbers af patients were studied to detcet any difference between drugs. Aa ranitidine is effective with administration twice daily, patient compliance may be better than with the 4 times daily treatment regimen adopted with cimetidine, though has not yet to be adequately demonstrated. There were no significant side-effects, either ranitidine or cimetidine, to the administration of the drug, except a case of dyspepsia on cimetidine regimen.
Cimetidine ; Duodenal Ulcer ; Dyspepsia ; Histamine ; Humans ; Outpatients ; Patient Compliance ; Peptic Ulcer* ; Ranitidine ; Stomach Ulcer

No abstract available.
Graves Disease* ; Humans ; Liver Function Tests* ; Liver*

No abstract available.
Drug Therapy* ; Lung Neoplasms* ; Lung*

BACKGROUND/AIMS: Although the only therapy of proven benefit for chronic hepatitis C is interferon alpha, the rate of sustained response after treatment with interferon is less than 25%. A 6-month course of combination therapy with interferon and ribavirin was associated with higher rate of long-term response than either interferon or ribavirin alone. Pilot studies suggested that combination of interferon and ursodeoxy-cholic acid (UDCA) resulted in higher biochemical response than interferon alone. We investigated the rates of end of treatment response(ETR) and sustained response(SR) of combination therapy of interferon e2a, ribavirin and UDCA and compared it with interferon a 2a alone. METHODS: Ninty-five naive patients with chronic hepatitis C who have been positive for anti-HCV by 3rd generation EIA and HCV RNA by RT-PCR and had elevated level of ALT over 6 months were included. They were assigned to three groups. Thirty seven patients in group 1 were treated with interferon a 2a (3MU thrice weekly) in combination with ribavirin (600mg/day) and UDCA (600mg/day) for 6 months. Twenty nine patients in group 2 were treated with the same dose of interferon a 2a alone for 6 months. Changes of ALT and HCV RNA were observed over 12 months (average 3029 mos) after the end of treatment in both groups. Twenty nine patients in group 3 were observed over 12 months without antiviral treatment. HCV genotypes were tested by Innop-Lipa in 24 patients in group 1. RESULTS: In group 1, not only ETR (68%) but also 12 month SR rate (54%) was significantly higher than group 2(31%, 21% respectively). There was no difference in relapse rate between two groups. The level of ALT became normalized and HCV RNA negative within 1 month after treatment in most responders in group l. Genotype 1b was associated with lower ETR and SR than non-lb, although not significant stastistically. CONCLUSION: Both the ETR and 12 month SR rate were significantly higher after combination treatment of interferon a 2a, ribavirin and UDCA than interferon e 2a alone in chronic hepatitis C. It is suggested that this combination is preferable to interferon alone in the treatment of naive patients with chronic hepatitis C.
Genotype ; Hepatitis C, Chronic* ; Hepatitis, Chronic* ; Humans ; Interferon-alpha* ; Interferons* ; Recurrence ; Ribavirin* ; RNA

We herein describe two cases of sudoriparous angioma consisting of increased number of eccrine sweat glands associated with angiomatous vascular channels. Case 1 is a 16 year-old girl developing two, painful and tender cavernous hemangiomas which sweated whenever compressed. These were located on her left gluteal area since early childhood. The biopsy specimen revealed an increased number of cystically dilated eccrine glands in the mid-dermis in addition to vascular components in the lower dermis. Case 2 is a five year-old girl manifesting non-tender, slightly hyperhidrotic nevus flammeus-like eruption on her left suprapopliteal area since birth, the biapsy apecimen of which revealed an increased number of eccrine glands admixed with capillary hemangioma in the mid-dermis.
Adolescent ; Biopsy ; Dermis ; Eccrine Glands ; Female ; Hemangioma* ; Hemangioma, Capillary ; Hemangioma, Cavernous ; Humans ; Nevus ; Parturition ; Sweat ; Sweat Glands

No abstract available.
Emergencies* ; Emergency Service, Hospital* ; Humans ; Statistics as Topic*